NF-kB p65 expression is a favorable prognostic factor in high-grade serous ovarian carcinoma

被引：0
|
作者：
Liu, J. [1 ]
Rosen, D. G. [1 ]
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
来源：
MODERN PATHOLOGY | 2007年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
942
引用
收藏
页码：206A / 206A
页数：1
相关论文
共 50 条
  • [21] Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma
    Siamakpour-Reihani, Sharareh
    Owzar, Kouros
    Jiang, Chen
    Turner, Taylor
    Deng, Yiwen
    Bean, Sarah M.
    Horton, Janet K.
    Berchuck, Andrew
    Marks, Jeffrey R.
    Dewhirst, Mark W.
    Secord, Angeles Alvarez
    GYNECOLOGIC ONCOLOGY, 2015, 139 (01) : 23 - 29
  • [22] Prognostic gene expression signature for high-grade serous ovarian cancer
    Millstein, J.
    Budden, T.
    Goode, E. L.
    Anglesio, M. S.
    Talhouk, A.
    Intermaggio, M. P.
    Leong, H. S.
    Chen, S.
    Elatre, W.
    Gilks, B.
    Nazeran, T.
    Volchek, M.
    Bentley, R. C.
    Wang, C.
    Chiu, D. S.
    Kommoss, S.
    Leung, S. C. Y.
    Senz, J.
    Lum, A.
    Chow, V
    Sudderuddin, H.
    Mackenzie, R.
    George, J.
    Fereday, S.
    Hendley, J.
    Traficante, N.
    Steed, H.
    Koziak, J. M.
    Kobel, M.
    McNeish, I. A.
    Goranova, T.
    Ennis, D.
    Macintyre, G.
    De Silva, D. Silva
    Ramon y Cajal, T.
    Garcia-Donas, J.
    Hernando Polo, S.
    Rodriguez, G. C.
    Cushing-Haugen, K. L.
    Harris, H. R.
    Greene, C. S.
    Zelaya, R. A.
    Behrens, S.
    Fortner, R. T.
    Sinn, P.
    Herpel, E.
    Lester, J.
    Lubinski, J.
    Oszurek, O.
    Toloczko, A.
    ANNALS OF ONCOLOGY, 2020, 31 (09) : 1240 - 1250
  • [23] Characterisation of protein kinases targeting p65 NF-KB phosphorylation and transactivation
    Buss, H
    Schmitz, L
    Dörrie, A
    Resch, K
    Kracht, M
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2002, 365 : R56 - R56
  • [24] VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer
    Liju Zong
    Yuncan Zhou
    Ming Zhang
    Jie Chen
    Yang Xiang
    Cancer Immunology, Immunotherapy, 2020, 69 : 33 - 42
  • [25] VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer
    Zong, Liju
    Zhou, Yuncan
    Zhang, Ming
    Chen, Jie
    Xiang, Yang
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (01) : 33 - 42
  • [26] Evaluation of the prognostic potential of histopathological subtyping in high-grade serous ovarian carcinoma
    Zelisse, Hein S.
    Hwan, Robin A.
    van de Vijver, Marc J.
    Dijk, Frederike
    Mom, Constantijne H.
    Hooijer, Gerrit K. J.
    van Gent, Mignon D. J. M.
    Snijders, Malou L. H.
    VIRCHOWS ARCHIV, 2024, 486 (2) : 381 - 391
  • [27] Prognostic impact of extracellular miRNAs in patients with high-grade serous ovarian carcinoma
    Yoshida, Kosuke
    Yokoi, Akira
    Matsuzaki, Juntaro
    Kato, Tomoyasu
    Ochiya, Takahiro
    Kajiyama, Hiroaki
    Yamamoto, Yusuke
    CANCER SCIENCE, 2022, 113 : 1788 - 1788
  • [28] Evaluation of the prognostic potential of histopathological subtyping in high-grade serous ovarian carcinoma
    Zelisse, Hein
    Van De Vijver, Marc
    Dijk, Frederike
    Mom, Constantijne
    Gent, Mignon Van
    Snijders, Malou
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A367 - A367
  • [29] Prognostic significance of differential expression of angiogenic genes in women with invasive high-grade serous ovarian carcinoma
    Siamakpour-Reihani, Sharareh
    Owzar, Kouros
    Jiang, Chen
    Turner, Taylor
    Berchuck, Andrew
    Marks, Jeffrey
    Dewhirst, Mark
    Secord, Angeles Alvarez
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [30] Loss of NF1 Expression Occurs at Significant Frequency in Tubo-Ovarian High-grade Serous Carcinoma and is Associated with Other Favorable Biomarkers
    Alshamma, Zainab
    Kang, Eun-Young
    Cook, Linda
    Fu, Yangxin
    Lee, Cheng-Han
    Reuss, David
    Koebel, Martin
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 714 - 715
12345